Abstract 19978: Circulating Microrna-145, Microrna-3619 and Microrna-486 Are Associated With In-stent Restenosis
Introduction: MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression in many disease settings including cardiovascular disease. miRNAs are critically involved in many biological processes in neointimal hyperplasia after coronary artery stenting. Recently, many studies have shown that miRNAs can be detected in circulating blood.
Hypothesis: The hypothesis of this study is miRNAs can be used as novel biomarkers for in-stent restenosis (ISR).
Methods: Coronary artery disease patients (n=80), who received 9 months angiographic follow-up after first PCI with drug-eluting stent implantation were analyzed. There are no significant differences of risk factors and demographic characteristics between ISR group (n=35) and non-ISR group (n=45). MicroRNA Microarray using affymetrix miRNA4.0 Array and Agilent miRNA Microarray were performed with pooled samples of baseline and 9 month follow-up plasma samples in both group.
Results: Microarray data showed significant differences (fold change >1.5) in the expression levels of miR-3157, miR-3619, miR-17-5p, let7b and miR-486 between ISR and non-ISR group. These miRNAs and other previously reported microRNAs including miR-143, miR-145, miR-92a, miR-222 and miR-34a were validated by quantitative real-time polymerase chain reaction in baseline and follow-up plasma samples of individual patient. The expression levels of miR-145 (p<0.05) and miR-3619 (p<0.05) are significantly decreased in ISR group and increased in non-ISR group. The expression level of miR-486 (p<0.05) is significantly decreased in non-ISR group and increased in ISR group.
Conclusions: miR-145, miR-3619 and miR-486 can be used as potential molecular markers and therapeutic targets for ISR.
Author Disclosures: S. Lee: None. I. Kang: None. J. Chung: None. K. Kwon: None.
- © 2014 by American Heart Association, Inc.